The renoprotective effects of pentoxifylline: beyond its role in diabetic nephropathy

References

1. Sun HK, Lee YM, Han KH, Kim HS, Ahn SH, Han SY. Phosphodieste rase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney. Korean J Intern Med 2012;27:163-170. https://doi.org/10.3904/kjim.2012.27.2.163
2. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47-52.
3. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE)4 inhibitors: anti-inf lammatory drugs of the future? Trends Pharmacol Sci 1997;18:164-171. https://doi.org/10.1016/S0165-6147(97)90613-1
4. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273-3277. https://doi.org/10.1001/jama.289.24.3273
5. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006;55:1832-1839. https://doi.org/10.2337/db05-1620
6. MacIsaac RJ, Panagiotopoulos S, McNeil KJ, et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care 2006;29:1560-1566.2009;31:848-854.